secwatch.observer — SEC 8-K summary
======================================

Issuer:     CLARIVATE PLC (CLVT)
CIK:        0001764046
Form:       8-K
Filed at:   2026-10-06T20:29:39+00:00
Accession:  0001764046-26-000117
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Clarivate closes $600M sale of Life Sciences & Healthcare to Altaris; segment head Levy departs
--------------------------------------------------------------------------------

- Deal consideration: $500M cash at closing plus a $75M unsecured senior note from an Altaris affiliate and $25M deferred cash payable by January 31, 2028.
- Henry Levy, President, Life Sciences & Healthcare, terminated employment at closing; separation agreement follows the retention agreement disclosed July 6, 2026.
- Clarivate will use proceeds to reduce debt; remaining portfolio is Academia & Government (Web of Science, ProQuest, Alma, Vega) and Intellectual Property (IPOne, Derwent, CompuMark, IPfolio).
- Q3 2026 results are set for November 3, 2026, when Clarivate will update full-year 2026 guidance to reflect the divestiture.
- Pro forma condensed balance sheet as of June 30, 2026 and statements of operations for 2023-2025 and 1H26 to be filed by October 13, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764046/000176404626000117/0001764046-26-000117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764046/000176404626000117/clvt-20261006.htm
  HTML page:      https://secwatch.observer/filing/0001764046-26-000117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer